Anton P Porsteinsson, Lea T Drye, Bruce G Pollock, D P Devanand, Constantine Frangakis, Zahinoor Ismail, Christopher Marano, Curtis L Meinert, Jacobo E Mintzer, Cynthia A Munro, Gregory Pelton, Peter V Rabins, Paul B Rosenberg, Lon S Schneider, David M Shade, Daniel Weintraub, Jerome Yesavage, Constantine G Lyketsos
IMPORTANCE: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. OBJECTIVE: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, and tolerability. DESIGN, SETTING, AND PARTICIPANTS: The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013...
February 19, 2014: JAMA